Tesla stock surges 12% despite falling short on Q1 earnings. Investors optimistic about future revenue, backed by upgraded rating and positive catalysts.
GM exceeded earnings expectations, with a 7.6% increase in sales and adjusted EPS of $2.62. Analysts have positive outlook on strong margins, EV progress, and capital allocation. Stock dips but trading up. Price targets range from $45-$75.
Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN-978 potential for autoimmune diseases, particularly systemic lupus erythematosus.